Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in late-stage studies for ovarian and endometrial cancer.
The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C. A similar dynamic is now playing out between Eli Lilly and Novo Nordisk in the obesity space, with some key differences.
The industry’s ability to generate a return on billions of dollars of investment rests on a heavily regulated supply chain defined by time-pressured logistics.
Nasty behavior by individuals at client companies toward auditors is widespread and can negatively affect auditor judgment, according a new academic study.
When valuing a company, a valuation analyst can play a critical role in identifying potential fraud risks and assessing whether management has implemented adequate measures.